Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors

Código QR

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors

Guardado en:

Detalles Bibliográficos
Autores principales:	Zheng-Hang Wang, Lin Shen
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2018
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/91ffb87ed5424e9fa51855f3125993c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Sireesha Upadhrasta, et al.
Publicado: (2019)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Xiaoyin Bai, et al.
Publicado: (2021)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
por: Marina A. Lyadova, et al.
Publicado: (2021)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Rilan Bai, et al.
Publicado: (2021)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
por: Kennedy Yao Yi Ng, et al.
Publicado: (2021)

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Despina Michailidou, et al.
Publicado: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
por: Ke Cheng, et al.
Publicado: (2021)

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
por: Tomas G Neilan, et al.
Publicado: (2021)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Zhenghang Wang, et al.
Publicado: (2021)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Ying Jing, et al.
Publicado: (2020)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publicado: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Di Wang, et al.
Publicado: (2021)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Pan Shen, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
por: Can Öztürk, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
por: Paolo Antonio Ascierto, et al.
Publicado: (2021)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Yan‐Xing Chen, et al.
Publicado: (2021)

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Publicado: (2021)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
por: Kun-Hsing Yu, et al.
Publicado: (2021)

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
por: Feicheng Wang, et al.
Publicado: (2021)

Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database
por: Yifan Zeng, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

The roles of exosomal immune checkpoint proteins in tumors
por: Cheng Xing, et al.
Publicado: (2021)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: Susan M. O’Brien, et al.
Publicado: (2021)

Indicators of responsiveness to immune checkpoint inhibitors
por: Bradley D. Shields, et al.
Publicado: (2017)

A Deep Learning-Based Text Classification of Adverse Nursing Events
por: Wenjing Lu, et al.
Publicado: (2021)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: Xiujing He, et al.
Publicado: (2021)

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
por: Theresa L Walunas, et al.
Publicado: (2021)

The Mediating Processes between Depression and Cardiac Adverse Events
por: R Bagherian,, et al.
Publicado: (2011)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kyoichi Kaira, et al.
Publicado: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Shinsuke Suzuki, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age
por: Raffaella Calabretta, et al.
Publicado: (2021)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
por: Zhihao Lu, et al.
Publicado: (2021)

A decade of immune-checkpoint inhibitors in cancer therapy
por: Caroline Robert
Publicado: (2020)

Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency
por: Katsunori Manaka, et al.
Publicado: (2021)

Auricular acupressure for adverse events following immunization related to COVID-19 vaccine injection: study protocol for a multicenter, three-arm, blinded randomized controlled trial
por: Qinwei Fu, et al.
Publicado: (2021)

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
por: Pottayil G. Sasikumar, et al.
Publicado: (2021)